A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL PROOF OF CONCEPT STUDY TO EVALUATE THE EFFECTS OF MULTIPLE ORAL DOSES OF TASIMELTEON AND MATCHING PLACEBO IN TRAVELERS WITH JET LAG DISORDER

INTERVENTION: Trade Name: HETLIOZ® Product Name: Tasimelteon (HETLIOZ®) Product Code: VEC‐162 Pharmaceutical Form: Capsule Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use CONDITION: Jet Lag Disorder (JLD) ; MedDRA version: 20.0 Level: PT Classification code 10040984 Term: Sleep disorder System Organ Class: 10037175 ‐ Psychiatric disorders Therapeutic area: Not possible to specify PRIMARY OUTCOME: Main Objective: To assess the effects of tasimelteon 20 mg on nighttime sleep parameters as measured by Polysomnography (PSG) after transmeridian travel Primary end point(s): The primary endpoint is the effectoftasimelteon 20mg on nighttime sleep parameters as measured by Polysomnography (PSG)aftertransmeridian travel.. The primary efficacy analysis will be based on the ITT population. Secondary Objective: Key Secondary Objectives:; 1. To assess the effects of tasimeleton 20mg on nighttime objective parameters.; 2. To assess the effects of tasimeleton 20mg on nighttime subjective parameters.; 3. To assess the effect of tasimeleton 20mg on a daytime objective parameter.; 4. To assess the effects of tasimeleton 20mg on daytime subjective parameters.; 5. To assess the effects of tasimeleton 20mg as measured by a combined scale of nighttime and daytime symptoms. SECONDARY OUTCOME: Secondary end point(s): The secondary efficacy outcomes include: ; ‐ To assess the effects of tasimeleton 20mgonnighttime objective parameters ; ‐ To assess the effects of tasimeleton 20mg on nighttime subjective parameters ; ‐ To assess the effect of tasimeleton 20mg on a daytime objective parameter ; ‐ To assess the effects of tasimeleton 20mg on daytime subjective parameters ; ‐ To assess the effects of tasimeleton 20mgas measured by a combined scale of nighttime and daytime symptoms INCLUSION CRITERIA: 1. Ability and acceptance to provide written informed consent 2. Men or women between 18 – 75 years, inclusive 3. A Jet Lag Symptom Scale (JLSS) total score of = 4 AND at least one night of Sleep Efficiency = 85% during the first two thirds of any night. The JLSS will be determined as follows: Subjects will receive a score of 2 for Sleep Efficiency that is = 80% or receive a score of 1 if it is = 85% during the first two thirds of the 8‐hour sleep period on each night. Subjects will also receive a score of 2 for an average KSS score of = 6 for each day. All the scores across 3 nights and 3 days will be added as the total score ranging from 0 to 12. 4. Body Mass Index (BMI) of = 18 and = 30 kg/m2 (BMI = weight (kg)/ [height (m)]2) 5. Valid passport for international travel and fluent in English; 6. Males, non‐fecund females (i.e., surgically sterilized, if procedure was done 6 months before screening or subject is postmenopausal, without mense